Cargando…

PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression

INTRODUCTION: Clinical depression is usually treated in primary care with psychological therapies and antidepressant medication. However, when patients do not respond to at least two or more antidepressants within a depressive episode, they are considered to have treatment resistant depression (TRD)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Au-Yeung, Sheena Kristine, Griffiths, James, Roberts, Sophie, Edwards, Chloe, Yu, Ly-Mee, Bogacz, Rafal, Rendell, Jennifer, Attenburrow, Mary-Jane, Watson, Stuart, Chan, Fiona, Cipriani, Andrea, Cleare, Anthony, Harmer, Catherine J, Kessler, David, Evans, Jonathan, Lewis, Glyn, Singh, Ilina, Simon, Judit, Harrison, Paul J, Cowen, Phil, Shanyinde, Milensu, Geddes, John, Browning, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046747/ https://www.ncbi.nlm.nih.gov/pubmed/34810175 http://dx.doi.org/10.1136/ebmental-2021-300282

Ejemplares similares

An Experimental Medicine Investigation of the Effects of Subacute Pramipexole Treatment on Emotional Information Processing in Healthy Volunteers
por: Martens, Marieke Annie Gerdine, et al.
Publicado: (2021)

Enhanced Taste Recognition Following Subacute Treatment With The Dopamine D2/D3 Receptor Agonist Pramipexole in Healthy Volunteers
por: Kaltenboeck, Alexander, et al.
Publicado: (2022)

A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania
por: Sharpley, Ann L, et al.
Publicado: (2020)

Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study)
por: Azim, Lumbini, et al.
Publicado: (2021)

Pramipexole: new use for an old drug – the potential use of pramipexole in the treatment of restless legs syndrome
por: Benbir, Gulcin, et al.
Publicado: (2006)

Update on the use of pramipexole in the treatment of Parkinson’s disease
por: Constantinescu, Radu
Publicado: (2008)

Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease
por: Piedad, John C. P., et al.
Publicado: (2012)

Questions asked and answered in pilot and feasibility randomized controlled trials
por: Shanyinde, Milensu, et al.
Publicado: (2011)

Biochemical and genetic predictors and correlates of response to lamotrigine and folic acid in bipolar depression: Analysis of the CEQUEL clinical trial
por: Tunbridge, EM, et al.
Publicado: (2017)

Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden
por: Lindahl, Jesper, et al.
Publicado: (2023)

Pramipexole use and the risk of pneumonia
por: Ernst, Pierre, et al.
Publicado: (2012)

Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease
por: Eisenreich, Wolfram, et al.
Publicado: (2010)

Reply: long-term retention rate of pramipexole in the treatment of Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Oxford Lithium Trial (OxLith) of the early affective, cognitive, neural and biochemical effects of lithium carbonate in bipolar disorder: study protocol for a randomised controlled trial
por: Saunders, Kate E. A., et al.
Publicado: (2016)

Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study)
por: Marwood, L., et al.
Publicado: (2017)

Extended follow-up of a short total diet replacement programme: results of the Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET) randomised controlled trial at 3 years
por: Astbury, Nerys M., et al.
Publicado: (2021)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease
por: Hametner, Eva-Maria, et al.
Publicado: (2012)

Pramipexole in the Treatment of Refractory Depression in a Patient with Rapid Cycling Bipolar Disorder
por: Hegde, Aditya, et al.
Publicado: (2015)

Impact of peer review on reports of randomised trials published in open peer review journals: retrospective before and after study
por: Hopewell, Sally, et al.
Publicado: (2014)

Burning mouth syndrome responsive to pramipexol
por: Stuginski-Barbosa, J., et al.
Publicado: (2008)

Automatic behavior and communication due to pramipexole
por: Walker, Ruth H.
Publicado: (2016)

Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression
por: Godlewska, B R, et al.
Publicado: (2016)

Predicting Treatment Response in Depression: The Role of Anterior Cingulate Cortex
por: Godlewska, Beata R, et al.
Publicado: (2018)

Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
por: Antonini, Angelo, et al.
Publicado: (2011)

Does Pramipexole Treatment Improve Headache in Patients with Concomitant Migraine and Restless Legs Syndrome?
por: Suzuki, Keisuke, et al.
Publicado: (2013)

Chronic pramipexole treatment increases tolerance for sucrose in normal and ventral tegmental lesioned rats
por: Dardou, David, et al.
Publicado: (2015)

Effects of pramipexole treatment on the α-synuclein content in serum exosomes of Parkinson's disease patients
por: Luo, He-Ting, et al.
Publicado: (2016)

Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole
por: Ferrari-Toninelli, Giulia, et al.
Publicado: (2010)

Gold nanoclusters as prospective carriers and detectors of pramipexole
por: Si, Nguyen Thanh, et al.
Publicado: (2021)

The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial
por: Hori, Hiroaki, et al.
Publicado: (2012)

Comparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease: A randomized parallel-group trial
por: Ziaei, Ehsan, et al.
Publicado: (2022)

Restless legs syndrome: differential diagnosis and management with pramipexole
por: Brindani, Francesca, et al.
Publicado: (2009)

Pramipexole effects on startle gating in rats and normal men
por: Swerdlow, Neal R., et al.
Publicado: (2009)

Pramipexole Reduces Phosphorylation of α-Synuclein at Serine-129
por: Chau, Kai-Yin, et al.
Publicado: (2013)

Pramipexole and its Extended Release Formulation for Parkinson’s Disease
por: Fishman, Paul S.
Publicado: (2011)

Analysis of pramipexole dose–response relationships in Parkinson’s disease
por: Wang, Ying, et al.
Publicado: (2016)

Effect of Venlafaxine, Pramipexole, and Valsartan on Spermatogenesis in Male Rats
por: Saleem, Uzma, et al.
Publicado: (2020)

SAT-203 Misleading Diagnosis of Cushing’s Syndrome on Pramipexole
por: Pahomov, Elizabeth, et al.
Publicado: (2020)

High-degree atrioventricular heart block induced by pramipexole
por: Kanal, Yücel, et al.
Publicado: (2022)

Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease
por: Sun, Yongqi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qeocbbv8sqj0i2qf6h9p7e6ca1